Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report

New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease

(2015) R. Srinivasan et al.   CLINICAL CANCER RESEARCH

Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

(2014) Fred H. Menko et al.   Familial Cancer

Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer--Targeting the Warburg Effect in Cancer

(2013) W. M. Linehan et al.   CLINICAL CANCER RESEARCH

mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology

(2013) C. Betz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein Profiling of Blood Samples from Patients with Hereditary Leiomyomatosis and Renal Cell Cancer by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

(2012) Takao Kamai et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer

(2012) Youfeng Yang et al.   Cancer Genetics

Succination of Keap1 and Activation of Nrf2-Dependent Antioxidant Pathways in FH-Deficient Papillary Renal Cell Carcinoma Type 2

(2011) Lisa Kinch et al.   CANCER CELL

An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma

(2011) Aikseng Ooi et al.   CANCER CELL

Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling

(2011) Julie Adam et al.   CANCER CELL

Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma

(2011) Nobutaka Furuya et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

UOK 262 cell line, fumarate hydratase deficient (FH−/FH−) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer

(2009) Youfeng Yang et al.   CANCER GENETICS AND CYTOGENETICS

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

(2009) Wen Wee Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Axitinib for renal cell carcinoma

(2008) Guru Sonpavde et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY